Nu Skin Enterprises posts Q4 2025 EPS of USD 0.29, up from loss, on revenue of USD 370.3 million, down 16.9%

Reuters
Feb 13
<a href="https://laohu8.com/S/NU">Nu</a> Skin Enterprises posts Q4 2025 EPS of USD 0.29, up from loss, on revenue of USD 370.3 million, down 16.9%

Nu Skin Enterprises Inc. reported fourth quarter (Q4) 2025 revenue of USD 370.3 million, a decrease of 16.9%. Earnings per share $(EPS)$ for the period were USD 0.29. Gross margin reached 70.7%. The company reported an operating margin of 6.3% and an income tax rate of 20.3% in the quarter. Paid affiliates totaled 129,311 and sales leaders were 30,045. For the full year 2025 (FY 2025), revenue was USD 1.49 billion, down 14.3%. Full-year EPS was USD 3.18, or USD 1.27 excluding the Mavely gain and other charges. The company ended the year with 748,796 customers. Nu Skin highlighted ongoing transformation initiatives, focusing on the global launch of Prysm iO intelligent wellness devices and efforts to build sales leader alignment in the first half of the year. Management reaffirmed its annual revenue guidance for 2026 in the range of USD 1.35 billion to USD 1.50 billion and projected full-year EPS of USD 0.80 to USD 1.20, with a forecasted tax rate of 35%. First quarter 2026 revenue is expected to be between USD 320 million and USD 340 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nu Skin Enterprises Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212024157) on February 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10